Table 1

Leukocyte-endothelial cell interactions in T241 VC+ and MT tumors

GroupaTumor typebNt (cells/30 s)cNr (%)dNa (cells/mm2)e
BL MT 8.0 ± 1.422.3 ± 4.675.7 ± 39.9
VC + 9.0 ± 1.517.4 ± 3.563.2 ± 43.9
D3 MT DC101 11.0 ± 1.619.3 ± 3.4146.3 ± 46.7
VC+ DC1016.0 ± 1.614.3 ± 4.480.1 ± 65.6
MT IgG8.5 ± 1.815.0 ± 6.195.3 ± 47.5
VC+ IgG9.0 ± 2.120.4 ± 3.6112.4 ± 51.4
D6 MT DC101 14.0 ± 2.614.7 ± 4.0137.9 ± 37.9
VC+ DC10111.0 ± 2.019.7 ± 4.7143.1 ± 56.0
MT IgG 13.5 ± 1.815.8 ± 3.985.5 ± 51.4
VC+ IgG16.0 ± 2.018.5 ± 5.1101.3 ± 61.9
  • a D3, 3 days post-DC101 treatment initiation; D6, 6 days post-DC101 treatment initiation.

  • b DC101, DC101-treated; IgG, nonspecific rat IgG-treated.

  • c Total leukocyte flux/30 s.

  • d Percentage of rolling leukocytes.

  • e Number of adherent leukocytes/mm2. Data are mean ± SEM.